Log In
Print
BCIQ
Print
Print this Print this
 

TNT009

  Manage Alerts
Collapse Summary General Information
Company True North Therapeutics Inc.
DescriptionHumanized mAb against complement component 1 s subcomponent (C1S)
Molecular Target Complement component 1 s subcomponent (C1S)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Hematology (unspecified)
Indication DetailsTreat cold agglutinin disease (CAD); Treat hematologic disorders
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today